Navigation Links
New genetic techniques to combat lung cancer

New results on genetic techniques that are helping doctors diagnose and treat lung cancer were released today at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) in Geneva, Switzerland.

In one report (Abstract No. 81O; Friday 25th April, 16:30), Israeli researchers from Rosetta Genomics (Nasdaq:ROSG), a biotech company developing microRNA-based technologies for diagnostic and therapeutic applications, describe a test that helps make crucial distinctions between types of lung cancer. The researchers show the method can accurately distinguish between squamous and non-squamous forms of non-small-cell lung cancer based on the levels of different microRNA molecules found in tissue samples.

MicroRNAs are short RNA molecules that regulate many cancer-related processes. "Recently, with the launch of new targeted therapies for non-squamous, non-small-cell lung cancer, the importance of accurate, objective diagnosis has taken center stage. The ability of physicians to accurately differentiate squamous from non-squamous NSCLC may be used as important treatment guide," said Dr. Maya Gottfried, member of Rosetta Genomics Medical Advisory Board and head of the Lung Cancer Unit at Meir Medical Center in Kfar Saba, Israel. For example some treatments for non-squamous non-small-cell lung cancer can be deadly in patients with the squamous form of the disease. Researchers expect the test to be approved for use during 2008.

In another report (Abstract No. 106PD; Friday 25th April, 08:00), Italian researchers show that genetic analysis can help identify patients who are at high risk of relapse after surgery to remove lung cancer. Dr. Guido Natoli from Regina Elena National Cancer Institute in Rome reports that the three-gene 'signature' can help oncologists choose the best drug to treat with.

"The results are preliminary, but I think our signature may allow the oncologists to classify patients with stage I non-small-cell lung cancer who underwent curative surgical resection in high or low risk molecular category, beyond conventional predictors," says Dr. Natoli.

His group's test includes the gene LCK, which is an important marker of immune cell anticancer activity, DUSP-6 which regulates a signaling pathway involved in cancer spread, and ERCC1, which is thought to be a significant prognostic and therapeutic biomarker in non-small-cell lung cancer. "By gathering these findings we can improve not only the prognostic stratification of patients, but also the choice of the more appropriate adjuvant drug after surgery," Dr. Natoli said.


Contact: Vanessa Pavinato
European Society for Medical Oncology

Related medicine news :

1. Many Parents Share Genetic Test Findings With Kids
2. Genetic predisposition increases childhood asthma risk
3. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
4. Test Spots Genetic Damage Done by Smoking
5. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
6. Scientists highlight benefits of genetic research in sport, but warn of ethical concerns
7. Genetics Hold Promise, Challenges for Cancer Care
8. Researchers genetically engineer micro-organisms into tiny factories
9. Study Questions Genetic Screening for Treatable Diseases
10. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
11. Genetic variation affects smoking cessation treatment
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... companies, announced today that it has officially launched a sleek, mobile-ready and user-centric ... that his company’s new website clearly outlines the benefits that its SEO services ...
(Date:11/30/2015)... Garden City, NY (PRWEB) , ... December 01, ... ... (NAPW) honors Christina Colon as a 2015-2016 inductee into its ... for leadership in pharmacy. NAPW is the nation’s leading networking organization exclusively for ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live Very Well is ... insurance plans on . The multi-carrier insurance exchange platform offers individual ... allowing consumers to compare, quote and match plans to meet their needs. ...
(Date:11/30/2015)... ... November 30, 2015 , ... Stress, anxiety, illness, infection or even a need ... tumors? , Heather Spader, MD, a new pediatric neurosurgeon at Joe DiMaggio Children’s Hospital ... point to tumors. , “Bad headaches that don’t go away, that don’t ...
(Date:11/30/2015)... ... ... MOSI recently added two state-of-the-art augmented reality (AR) experiences from INDE Broadcast ... collection of interactive exhibits within the Kids In Charge! building. In collaboration with the ... closer than ever to a range of animals as they drink, sleep and play ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)...  QT Vascular Ltd., together with its subsidiaries (the ... TriReme Medical LLC and Quattro Vascular Pte. Ltd., collectively ... assembly and distribution of advanced therapeutic solutions for the ... announce that a three-judge panel of the ... Federal Circuit ("Federal Circuit") has unanimously granted the Group ...
(Date:11/30/2015)... ) has ... Market 2015-2019" report to their offering. ... of the "Orphan Drugs Market 2015-2019" ... and Markets ( ) has announced the ... report to their offering. ...
(Date:11/30/2015)... -- IBA Molecular North America, Inc. (IBAMNA), a U.S. leader ... as of January 1, 2016, it will do business ... rebrand the company reflects a refined vision for the ... relationship with Zevacor Molecular.  Both IBAMNA and Zevacor Molecular ... Peter Burke , Vice President Sales and ...
Breaking Medicine Technology: